{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T02:38:29Z","timestamp":1781836709504,"version":"3.54.5"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurosci"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is a neurodegenerative disorder characterized by protein aggregates mostly consisting of misfolded alpha-synuclein (\u03b1Syn). Progressive degeneration of midbrain dopaminergic neurons (mDANs) and nigrostriatal projections results in severe motor symptoms. While the preferential loss of mDANs has not been fully understood yet, the cell type-specific vulnerability has been linked to a unique intracellular milieu, influenced by dopamine metabolism, high demand for mitochondrial activity, and increased level of oxidative stress (OS). These factors have been shown to adversely impact \u03b1Syn aggregation. Reciprocally, \u03b1Syn aggregates, in particular oligomers, can impair mitochondrial functions and exacerbate OS. Recent drug-discovery studies have identified a series of small molecules, including NPT100-18A, which reduce \u03b1Syn oligomerization by preventing misfolding and dimerization. NPT100-18A and structurally similar compounds (such as NPT200-11\/UCB0599, currently being assessed in clinical studies) point towards a promising new approach for disease-modification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Induced pluripotent stem cell (iPSC)-derived mDANs from PD patients with a monoallelic\n                      <jats:italic>SNCA<\/jats:italic>\n                      locus duplication and unaffected controls were treated with NPT100-18A. \u03b1Syn aggregation was evaluated biochemically and reactive oxygen species (ROS) levels were assessed in living mDANs using fluorescent dyes. Adenosine triphosphate (ATP) levels were measured using a luminescence-based assay, and neuronal cell death was evaluated by immunocytochemistry.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared to controls, patient-derived mDANs exhibited higher cytoplasmic and mitochondrial ROS probe levels, reduced ATP-related signals, and increased activation of caspase-3, reflecting early neuronal cell death. NPT100-18A-treatment rescued cleaved caspase-3 levels to control levels and, importantly, attenuated mitochondrial oxidative stress probe levels in a compartment-specific manner and, at higher concentrations, increased ATP signals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings demonstrate that NPT100-18A limits neuronal degeneration in a human in vitro model of PD. In addition, we provide first mechanistic insights into how a compartment-specific antioxidant effect in mitochondria might contribute to the neuroprotective effects of NPT100-18A.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12868-025-00926-y","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T04:54:52Z","timestamp":1738040092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["NPT100-18A rescues mitochondrial oxidative stress and neuronal degeneration in human iPSC-based Parkinson\u2019s model"],"prefix":"10.1186","volume":"26","author":[{"given":"Julian E.","family":"Alecu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Sigutova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razvan-Marius","family":"Brazdis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"L\u00f6rentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marios Evangelos","family":"Bogiongko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anara","family":"Nursaitova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Regensburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Roybon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin M.","family":"Galler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Wrasidlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Winner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Prots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"926_CR1","doi-asserted-by":"publisher","first-page":"776847","DOI":"10.3389\/fpubh.2021.776847","volume":"9","author":"Z Ou","year":"2021","unstructured":"Ou Z, Pan J, Tang S, et al. Global trends in the incidence, prevalence, and years lived with disability of Parkinson\u2019s Disease in 204 Countries\/Territories from 1990 to 2019. Front Public Health. 2021;9:776847.","journal-title":"Front Public Health"},{"key":"926_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Elbaz A, Nichols E, et al. Global, regional, and national burden of Parkinson\u2019s disease, 1990\u20132016: a systematic analysis for the global burden of Disease Study 2016. Lancet Neurol. 2018;17:939\u201353.","journal-title":"Lancet Neurol"},{"key":"926_CR3","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet (London England). 2015;386:896\u2013912.","journal-title":"Lancet (London England)"},{"key":"926_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839\u201340.","journal-title":"Nature"},{"key":"926_CR5","doi-asserted-by":"crossref","unstructured":"Burr\u00e9 J, Sharma M, S\u00fcdhof TC. Cell Biology and Pathophysiology of \u03b1-Synuclein. Cold Spring Harbor perspectives in medicine 2018;8.","DOI":"10.1101\/cshperspect.a024091"},{"key":"926_CR6","first-page":"1663","volume-title":"Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro","author":"J Burr\u00e9","year":"2010","unstructured":"Burr\u00e9 J, Sharma M, Tsetsenis T, et al. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Volume 329. New York, N.Y.): Science; 2010. pp. 1663\u20137."},{"key":"926_CR7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature10324","volume":"477","author":"T Bartels","year":"2011","unstructured":"Bartels T, Choi JG, Selkoe DJ. \u03b1-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011;477:107\u201310.","journal-title":"Nature"},{"key":"926_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000355516","volume":"13","author":"D Selkoe","year":"2014","unstructured":"Selkoe D, Dettmer U, Luth E, et al. Defining the native state of \u03b1-synuclein. Neuro-degener Dis. 2014;13:114\u20137.","journal-title":"Neuro-degener Dis"},{"key":"926_CR9","doi-asserted-by":"crossref","unstructured":"Du X-Y, Xie X-X, Liu R-T. The Role of \u03b1-Synuclein Oligomers in Parkinson\u2019s Disease. Int J Mol Sci 2020;21.","DOI":"10.3390\/ijms21228645"},{"key":"926_CR10","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S0140-6736(04)17103-1","volume":"364","author":"M-C Chartier-Harlin","year":"2004","unstructured":"Chartier-Harlin M-C, Kachergus J, Roumier C, et al. \u03b1-synuclein locus duplication as a cause of familial Parkinson\u2019s disease. Lancet. 2004;364:1167\u20139.","journal-title":"Lancet"},{"key":"926_CR11","first-page":"841","volume-title":"Alpha-synuclein locus triplication causes Parkinson\u2019s disease","author":"AB Singleton","year":"2003","unstructured":"Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson\u2019s disease. Volume 302. New York, N.Y.): Science; 2003. p. 841."},{"key":"926_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nature17939","volume":"533","author":"F Soldner","year":"2016","unstructured":"Soldner F, Stelzer Y, Shivalila CS, et al. Parkinson-associated risk variant in distal enhancer of \u03b1-synuclein modulates target gene expression. Nature. 2016;533:95\u20139.","journal-title":"Nature"},{"key":"926_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.14806","author":"M Delenclos","year":"2019","unstructured":"Delenclos M, Burgess JD, Lamprokostopoulou A, et al. Cellular models of alpha-synuclein toxicity and aggregation. J Neurochem. 2019. https:\/\/doi.org\/10.1111\/jnc.14806.","journal-title":"J Neurochem"},{"key":"926_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/jnc.14808","volume":"150","author":"P Alam","year":"2019","unstructured":"Alam P, Bousset L, Melki R, et al. \u03b1-synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities. J Neurochem. 2019;150:522\u201334.","journal-title":"J Neurochem"},{"key":"926_CR15","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1093\/brain\/awu057","volume":"137","author":"E Rockenstein","year":"2014","unstructured":"Rockenstein E, Nuber S, Overk CR, et al. Accumulation of oligomer-prone \u03b1-synuclein exacerbates synaptic and neuronal degeneration in vivo. Brain J Neurol. 2014;137:1496\u2013513.","journal-title":"Brain J Neurol"},{"key":"926_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/bs.ircmb.2016.08.010","volume":"329","author":"N Cremades","year":"2017","unstructured":"Cremades N, Chen SW, Dobson CM. Structural characteristics of \u03b1-Synuclein oligomers. Int Rev cell Mol Biology. 2017;329:79\u2013143.","journal-title":"Int Rev cell Mol Biology"},{"key":"926_CR17","first-page":"1772","volume-title":"Yeast cells provide insight into alpha-synuclein biology and pathobiology","author":"TF Outeiro","year":"2003","unstructured":"Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Volume 302. New York, N.Y.): Science; 2003. pp. 1772\u20135."},{"key":"926_CR18","first-page":"1440","volume-title":"Structural basis of membrane disruption and cellular toxicity by \u03b1-synuclein oligomers","author":"G Fusco","year":"2017","unstructured":"Fusco G, Chen SW, Williamson PTF, et al. Structural basis of membrane disruption and cellular toxicity by \u03b1-synuclein oligomers. Volume 358. New York, N.Y.): Science; 2017. pp. 1440\u20133."},{"key":"926_CR19","doi-asserted-by":"publisher","first-page":"12924","DOI":"10.1074\/jbc.M306390200","volume":"279","author":"E Lindersson","year":"2004","unstructured":"Lindersson E, Beedholm R, H\u00f8jrup P, et al. Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem. 2004;279:12924\u201334.","journal-title":"J Biol Chem"},{"key":"926_CR20","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1038\/s41467-018-04422-2","volume":"9","author":"MHR Ludtmann","year":"2018","unstructured":"Ludtmann MHR, Angelova PR, Horrocks MH, et al. \u03b1-synuclein oligomers interact with ATP synthase and open the permeability transition pore in Parkinson\u2019s disease. Nat Commun. 2018;9:2293.","journal-title":"Nat Commun"},{"key":"926_CR21","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.bbrc.2007.02.163","volume":"356","author":"L Chen","year":"2007","unstructured":"Chen L, Jin J, Davis J, et al. Oligomeric alpha-synuclein inhibits tubulin polymerization. Biochem Biophys Res Commun. 2007;356:548\u201353.","journal-title":"Biochem Biophys Res Commun"},{"key":"926_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nm.4269","volume":"23","author":"YC Wong","year":"2017","unstructured":"Wong YC, Krainc D. \u03b1-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies. Nat Med. 2017;23:1\u201313.","journal-title":"Nat Med"},{"key":"926_CR23","doi-asserted-by":"publisher","first-page":"7813","DOI":"10.1073\/pnas.1713129115","volume":"115","author":"I Prots","year":"2018","unstructured":"Prots I, Grosch J, Brazdis R-M, et al. \u03b1-Synuclein oligomers induce early axonal dysfunction in human iPSC-based models of synucleinopathies. Proc Natl Acad Sci USA. 2018;115:7813\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"926_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.neulet.2010.09.061","volume":"486","author":"SJ Chinta","year":"2010","unstructured":"Chinta SJ, Mallajosyula JK, Rane A, et al. Mitochondrial \u03b1-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett. 2010;486:235\u20139.","journal-title":"Neurosci Lett"},{"key":"926_CR25","doi-asserted-by":"publisher","first-page":"21490","DOI":"10.1074\/jbc.M113.545749","volume":"289","author":"ES Luth","year":"2014","unstructured":"Luth ES, Stavrovskaya IG, Bartels T, et al. Soluble, prefibrillar \u03b1-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J Biol Chem. 2014;289:21490\u2013507.","journal-title":"J Biol Chem"},{"key":"926_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40478-019-0696-4","volume":"7","author":"X Wang","year":"2019","unstructured":"Wang X, Becker K, Levine N, et al. Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration. Acta Neuropathol Commun. 2019;7:41.","journal-title":"Acta Neuropathol Commun"},{"key":"926_CR27","doi-asserted-by":"crossref","first-page":"342ra78","DOI":"10.1126\/scitranslmed.aaf3634","volume":"8","author":"R Di Maio","year":"2016","unstructured":"Di Maio R, Barrett PJ, Hoffman EK, et al. \u03b1-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson\u2019s disease. Sci Transl Med. 2016;8:342ra78.","journal-title":"Sci Transl Med"},{"key":"926_CR28","doi-asserted-by":"publisher","first-page":"2105607","DOI":"10.1155\/2019\/2105607","volume":"2019","author":"G Cenini","year":"2019","unstructured":"Cenini G, Lloret A, Cascella R. Oxidative stress in neurodegenerative diseases: from a mitochondrial point of View. Oxidative Med Cell Longev. 2019;2019:2105607.","journal-title":"Oxidative Med Cell Longev"},{"key":"926_CR29","first-page":"256","volume-title":"Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism","author":"V Bonifati","year":"2003","unstructured":"Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Volume 299. New York, N.Y.): Science; 2003. pp. 256\u20139."},{"key":"926_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3389\/fneur.2013.00038","volume":"4","author":"J-F Trempe","year":"2013","unstructured":"Trempe J-F, Fon EA. Structure and function of Parkin, PINK1, and DJ-1, the three musketeers of Neuroprotection. Front Neurol. 2013;4:38.","journal-title":"Front Neurol"},{"key":"926_CR31","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1093\/hmg\/ddaa039","volume":"29","author":"R-M Brazdis","year":"2020","unstructured":"Brazdis R-M, Alecu JE, Marsch D, et al. Demonstration of brain region-specific neuronal vulnerability in human iPSC-based model of familial Parkinson\u2019s disease. Hum Mol Genet. 2020;29:1180\u201391.","journal-title":"Hum Mol Genet"},{"key":"926_CR32","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1093\/brain\/aww238","volume":"139","author":"W Wrasidlo","year":"2016","unstructured":"Wrasidlo W, Tsigelny IF, Price DL, et al. A de novo compound targeting \u03b1-synuclein improves deficits in models of Parkinson\u2019s disease. Brain. 2016;139:3217\u201336.","journal-title":"Brain"},{"key":"926_CR33","doi-asserted-by":"publisher","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","volume":"8","author":"DL Price","year":"2018","unstructured":"Price DL, Koike MA, Khan A, et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease. Sci Rep. 2018;8:16165.","journal-title":"Sci Rep"},{"key":"926_CR34","doi-asserted-by":"publisher","first-page":"E3679","DOI":"10.1073\/pnas.1617259114","volume":"114","author":"G Kouroupi","year":"2017","unstructured":"Kouroupi G, Taoufik E, Vlachos IS, et al. Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson\u2019s disease. PNAS. 2017;114:E3679\u201388.","journal-title":"PNAS"},{"key":"926_CR35","doi-asserted-by":"publisher","first-page":"16009","DOI":"10.1038\/npjparkd.2016.9","volume":"2","author":"S Holmqvist","year":"2016","unstructured":"Holmqvist S, Lehtonen \u0160, Chumarina M, et al. Creation of a library of induced pluripotent stem cells from parkinsonian patients. NPJ Parkinson\u2019s Disease. 2016;2:16009.","journal-title":"NPJ Parkinson\u2019s Disease"},{"key":"926_CR36","doi-asserted-by":"publisher","first-page":"113466","DOI":"10.1016\/j.expneurol.2020.113466","volume":"334","author":"K Simmnacher","year":"2020","unstructured":"Simmnacher K, Krach F, Schneider Y, et al. Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020;334:113466.","journal-title":"Exp Neurol"},{"key":"926_CR37","doi-asserted-by":"publisher","first-page":"e59252","DOI":"10.1371\/journal.pone.0059252","volume":"8","author":"P Reinhardt","year":"2013","unstructured":"Reinhardt P, Glatza M, Hemmer K, et al. Derivation and expansion using only small molecules of human neural progenitors for neurodegenerative disease modeling. PLoS ONE. 2013;8:e59252.","journal-title":"PLoS ONE"},{"key":"926_CR38","doi-asserted-by":"publisher","first-page":"14211","DOI":"10.1038\/srep14211","volume":"5","author":"A Sasaki","year":"2015","unstructured":"Sasaki A, Arawaka S, Sato H, et al. Sensitive western blotting for detection of endogenous Ser129-phosphorylated \u03b1-synuclein in intracellular and extracellular spaces. Sci Rep. 2015;5:14211.","journal-title":"Sci Rep"},{"key":"926_CR39","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"926_CR40","doi-asserted-by":"crossref","unstructured":"Seebauer L, Schneider Y, Drobny A et al. Interaction of Alpha Synuclein and Microtubule Organization Is Linked to Impaired Neuritic Integrity in Parkinson\u2019s Patient-Derived Neuronal Cells. International journal of molecular sciences 2022;23.","DOI":"10.3390\/ijms23031812"},{"key":"926_CR41","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.bbi.2024.08.015","volume":"122","author":"V Sigutova","year":"2024","unstructured":"Sigutova V, Xiang W, Regensburger M, et al. Alpha-synuclein fine-tunes neuronal response to pro-inflammatory cytokines. Brain Behav Immun. 2024;122:216\u201330.","journal-title":"Brain Behav Immun"},{"key":"926_CR42","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s00401-019-01993-2","volume":"137","author":"H Di","year":"2019","unstructured":"Di H, Sun X, Liao X, et al. Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity. Acta Neuropathol. 2019;137:939\u201360.","journal-title":"Acta Neuropathol"},{"key":"926_CR43","first-page":"5","volume":"1","author":"AG Yakovlev","year":"2004","unstructured":"Yakovlev AG, Faden AI. Mechanisms of neural cell death: implications for development of neuroprotective treatment strategies. NeuroRx J Am Soc Experimental Neurother. 2004;1:5\u201316.","journal-title":"NeuroRx J Am Soc Experimental Neurother"},{"key":"926_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41593-019-0556-3","volume":"23","author":"SM Graves","year":"2020","unstructured":"Graves SM, Xie Z, Stout KA, et al. Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain. Nat Neurosci. 2020;23:15\u201320.","journal-title":"Nat Neurosci"},{"key":"926_CR45","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s10495-007-0722-z","volume":"12","author":"KW Kinnally","year":"2007","unstructured":"Kinnally KW, Antonsson B. A tale of two mitochondrial channels, MAC and PTP, in apoptosis. Apoptosis Int J Program cell Death. 2007;12:857\u201368.","journal-title":"Apoptosis Int J Program cell Death"},{"key":"926_CR46","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1073\/pnas.040556597","volume":"97","author":"A Hartmann","year":"2000","unstructured":"Hartmann A, Hunot S, Michel PP, et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson\u2019s disease. Proc Natl Acad Sci USA. 2000;97:2875\u201380.","journal-title":"Proc Natl Acad Sci USA"},{"key":"926_CR47","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/cdd.2009.180","volume":"17","author":"M D\u2019Amelio","year":"2010","unstructured":"D\u2019Amelio M, Cavallucci V, Cecconi F. Neuronal caspase-3 signaling: not only cell death. Cell Death Differ. 2010;17:1104\u201314.","journal-title":"Cell Death Differ"},{"key":"926_CR48","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.tins.2012.06.004","volume":"35","author":"M D\u2019Amelio","year":"2012","unstructured":"D\u2019Amelio M, Sheng M, Cecconi F. Caspase-3 in the central nervous system: beyond apoptosis. Trends Neurosci. 2012;35:700\u20139.","journal-title":"Trends Neurosci"},{"key":"926_CR49","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.stem.2017.09.014","volume":"21","author":"RA Barker","year":"2017","unstructured":"Barker RA, Parmar M, Studer L, et al. Human trials of stem cell-derived dopamine neurons for Parkinson\u2019s Disease: Dawn of a new era. Cell Stem Cell. 2017;21:569\u201373.","journal-title":"Cell Stem Cell"},{"key":"926_CR50","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S1474-4422(09)70238-8","volume":"8","author":"DW Dickson","year":"2009","unstructured":"Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson\u2019s disease: refining the diagnostic criteria. Lancet Neurol. 2009;8:1150\u20137.","journal-title":"Lancet Neurol"},{"key":"926_CR51","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1093\/brain\/awt192","volume":"136","author":"JH Kordower","year":"2013","unstructured":"Kordower JH, Olanow CW, Dodiya HB, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson\u2019s disease. Brain. 2013;136:2419\u201331.","journal-title":"Brain"},{"key":"926_CR52","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.parkreldis.2011.01.003","volume":"17","author":"Y Winter","year":"2011","unstructured":"Winter Y, von Campenhausen S, Arend M, et al. Health-related quality of life and its determinants in Parkinson\u2019s disease: results of an Italian cohort study. Parkinsonism Relat Disord. 2011;17:265\u20139.","journal-title":"Parkinsonism Relat Disord"},{"key":"926_CR53","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1093\/hmg\/ddt644","volume":"23","author":"S Havlicek","year":"2014","unstructured":"Havlicek S, Kohl Z, Mishra HK, et al. Gene dosage-dependent rescue of HSP neurite defects in SPG4 patients\u2019 neurons. Hum Mol Genet. 2014;23:2527\u201341.","journal-title":"Hum Mol Genet"},{"key":"926_CR54","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.stem.2018.06.015","volume":"23","author":"A Sommer","year":"2018","unstructured":"Sommer A, Marxreiter F, Krach F, et al. Th17 lymphocytes induce neuronal cell death in a human iPSC-Based model of Parkinson\u2019s Disease. Cell Stem Cell. 2018;23:123\u2013e1316.","journal-title":"Cell Stem Cell"}],"container-title":["BMC Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-025-00926-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12868-025-00926-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12868-025-00926-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T07:10:25Z","timestamp":1744009825000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurosci.biomedcentral.com\/articles\/10.1186\/s12868-025-00926-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["926"],"URL":"https:\/\/doi.org\/10.1186\/s12868-025-00926-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4400225\/v1","asserted-by":"object"}]},"ISSN":["1471-2202"],"issn-type":[{"value":"1471-2202","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"assertion":[{"value":"10 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was performed in accordance with the Declaration of Helsinki. Human iPSCs derived from human dermal fibroblasts were obtained from the stem cell unit of the Friedrich-Alexander University Erlangen-N\u00fcrnberg. Written informed consent was received from voluntary donors of skin biopsies prior to inclusion in the study at the Movement Disorder Clinic at the Department of Molecular Neurology, University Hospital Erlangen. All experiments using human iPSC-derived cells were conducted in accordance with the Institutional Review Board approval (Nr. 259_17B), as well as national and European Union directives. The iPSC line CSC-1 was generated from fibroblasts obtained with informed consent and after ethical committee approval at the Parkinson Institute in Milan. The permit for reprogramming of CSC-1 was delivered by the Swedish Work Environment Authority (Arbetsmilj\u00f6verket, reg.-no.: 20200 \u2212 3211).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"WW is a cofounder of Neuropore Therapies, Inc. (San Diego, CA, USA). The other authors declare to have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8"}}